Bernd Gerber

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi [Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003]
    B Gerber
    I Frauenklinik der LMU München, Germany
    Zentralbl Gynakol 125:315-21. 2003
  2. ncbi [Juvenile gigantomastia. Case report and literature survey]
    B Gerber
    I Frauenklinik Innenstadt der Ludwig Maximilians Universität München
    Zentralbl Gynakol 126:167-9. 2004
  3. ncbi Nutrition and lifestyle factors on the risk of developing breast cancer
    Bernd Gerber
    Department of Obstetrics and Gynaecology, University of Rostock, Germany
    Breast Cancer Res Treat 79:265-76. 2003
  4. ncbi Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure
    Bernd Gerber
    Department of Obstetrics and Gynecology, LMU Munich, Maistrasse 11, 80337 Munich, Germany
    Ann Surg 238:120-7. 2003
  5. ncbi [Reduction of the risk of breast cancer]
    B Gerber
    I Frauenklinik Klinikum Innenstadt, Ludwig Maximilians Universitat Munchen, Munich
    Zentralbl Gynakol 125:6-16. 2003
  6. ncbi Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread
    Bernd Gerber
    Department of Obstetrics and Gynecology, Klinikum Innenstadt, Ludwig Maximilians University Munich, Munich, Germany
    Breast Cancer Res Treat 82:29-37. 2003
  7. ncbi How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis
    Toralf Reimer
    Department of Obstetrics and Gynecology, University of Rostock, Klinikum Suedstadt, Suedring 81, 18059 Rostock, Germany
    Ann Surg Oncol 15:472-7. 2008
  8. ncbi Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
  9. ncbi Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence
    Udo Jeschke
    Ludwig Maximilians University of Munich, Department of Obstetrics and Gynecology, 80337 Munich, Germany
    Anticancer Res 27:1969-74. 2007
  10. ncbi Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases
    Naim Shabani
    I. Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337 Munich, Germany
    Anticancer Res 25:1761-4. 2005

Detail Information

Publications48

  1. ncbi [Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003]
    B Gerber
    I Frauenklinik der LMU München, Germany
    Zentralbl Gynakol 125:315-21. 2003
    ..quot;Older" patients will get only limited advantage of chemoendocrine treatment compared to endocrine treatment alone. Preliminary treatment recommendations comprise a wide range of possible treatment options...
  2. ncbi [Juvenile gigantomastia. Case report and literature survey]
    B Gerber
    I Frauenklinik Innenstadt der Ludwig Maximilians Universität München
    Zentralbl Gynakol 126:167-9. 2004
    ..It is thus suggested that the etiology of this disease might be related to a local hypersensitivity to estrogen. Mediactions (Tamoxifen) are mostly ineffective. The treatment consisted of reduction plasty...
  3. ncbi Nutrition and lifestyle factors on the risk of developing breast cancer
    Bernd Gerber
    Department of Obstetrics and Gynaecology, University of Rostock, Germany
    Breast Cancer Res Treat 79:265-76. 2003
    ..A health lifestyle, consisting of 'healthy diet', physical activity, renunciation of stimulants, is recommended from childhood throughout life...
  4. ncbi Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure
    Bernd Gerber
    Department of Obstetrics and Gynecology, LMU Munich, Maistrasse 11, 80337 Munich, Germany
    Ann Surg 238:120-7. 2003
    ..Is skin-sparing mastectomy (SSM) with conservation of the Nipple-Areola Complex (NAC) and immediate autologous reconstruction as safe in oncologic terms as SSM with resection of the NAC as modified radical mastectomy (MRM)?..
  5. ncbi [Reduction of the risk of breast cancer]
    B Gerber
    I Frauenklinik Klinikum Innenstadt, Ludwig Maximilians Universitat Munchen, Munich
    Zentralbl Gynakol 125:6-16. 2003
    ..A health lifestyle, consisting of "healthy diet", physical activity, renunciation of stimulants, is recommended from childhood throughout life...
  6. ncbi Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread
    Bernd Gerber
    Department of Obstetrics and Gynecology, Klinikum Innenstadt, Ludwig Maximilians University Munich, Munich, Germany
    Breast Cancer Res Treat 82:29-37. 2003
    ..Is a perioperative metastatic screening program indicated in patients presenting with primary operable breast cancer and no signs of distant metastases?..
  7. ncbi How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis
    Toralf Reimer
    Department of Obstetrics and Gynecology, University of Rostock, Klinikum Suedstadt, Suedring 81, 18059 Rostock, Germany
    Ann Surg Oncol 15:472-7. 2008
    ..In the era of potential avoidance of axillary surgery we evaluate the impact of pathologic nodal status for adjuvant treatment decisions...
  8. ncbi Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
    ..Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery...
  9. ncbi Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence
    Udo Jeschke
    Ludwig Maximilians University of Munich, Department of Obstetrics and Gynecology, 80337 Munich, Germany
    Anticancer Res 27:1969-74. 2007
    ....
  10. ncbi Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases
    Naim Shabani
    I. Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337 Munich, Germany
    Anticancer Res 25:1761-4. 2005
    ..On the basis of these results, we speculate that glycodelin expression could be used as a prognostic marker for breast cancer. This has to be confirmed in larger studies...
  11. ncbi Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology
    Bernd Gerber
    Department of Obstetrics and Gynecology, Klinikum Innenstadt, Ludwig Maximilians University, Munich, Germany
    Clin Cancer Res 12:1245-50. 2006
    ..To investigate the effect of switching from adjuvant tamoxifen to anastrozole (Arimidex) treatment in postmenopausal women with endocrine-responsive breast cancer and histologically proven tamoxifen-induced benign endometrial pathology...
  12. ncbi Breast reconstruction with a latissimus dorsi flap in a patient who had had her axillary lymph nodes irradiated in childhood
    Toralf Reimer
    Department of Obstetrics and Gynaecology, University of Rostock, Klinikum Suedstadt, Rostock, Germany
    Scand J Plast Reconstr Surg Hand Surg 42:48-50. 2008
    ..Twenty-two years later she developed a secondary breast carcinoma which was managed by skin-sparing mastectomy and immediate reconstruction with a pedicled latissimus dorsi flap...
  13. ncbi Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
    Brigitte Rack
    Department of Gynecology and Obstetrics, I Frauenklinik, Klinikum der Ludwig Maximilians Universitaet, Munich, Germany
    Breast Cancer Res Treat 82:83-92. 2003
    ..Persisting prognostic impact after relapse would identify lymph node status as a marker for tumor biology, in contrast to a simply time-dependent phenomenon...
  14. ncbi Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence
    Udo Jeschke
    Department of Obstetrics and Gynaecology, Ludwig Maximilians University of Munich, Maistrasse 11, 80337 Munich, Germany
    Oncol Rep 13:413-9. 2005
    ..In contrast, cases of breast cancer with metastatic infiltration and recurrence show weak expression of glycodelin. On the basis of these results, we speculate that glycodelin could be used as a prognostic marker for breast cancer...
  15. ncbi Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone
    Ioannis Mylonas
    Ludwig Maximilians University Munich, 1st Department of Obstetrics and Gynecology, 80337 Munich, Germany
    Anticancer Res 25:1719-23. 2005
    ....
  16. ncbi Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis
    Claudia Röwer
    Proteome Center Rostock, University of Rostock, Rostock, Germany
    Int J Clin Exp Pathol 4:454-67. 2011
    ..Such comprehensive data sets are needed for both, pathway analyses and for "next generation clinical diagnostics" approaches...
  17. ncbi The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study
    Bernd Gerber
    Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany
    Ann Surg 249:461-8. 2009
    ..To find out if skin sparing mastectomy (SSM) and nipple sparing mastectomy (NSM) with immediate autologous reconstruction as safe in oncological terms as modified radical mastectomy (MRM)...
  18. ncbi Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis
    Udo Jeschke
    I Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, Munich, Germany
    Anticancer Res 25:1615-22. 2005
    ..In this study, we analysed the combined expression of SLeX, SLea, Cathepsin-D and E-cadherin in breast carcinoma in situ, invasive carcinomas without metastasis and invasive carcinomas with lymph node metastasis...
  19. ncbi Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma
    Claudia Röwer
    Proteome Center Rostock, Department for Proteome Research, Institute of Immunology, Medical Faculty, University of Rostock, Schillingallee 69, P O Box 100 888, Rostock 18055, Germany
    J Am Soc Mass Spectrom 22:440-56. 2011
    ....
  20. ncbi Pregnancy-associated breast cancer -- special features in diagnosis and treatment
    Wolfgang Janni
    Obstetrics and Gynecology Clinic and Polyclinic of Ludwig Maximilian University, Klinikum Innenstadt, Munchen, Germany
    Onkologie 29:107-12. 2006
    ..The following article summarizes the special features of the diagnosis and primary therapy of pregnancy-associated breast cancer with particular consideration of cytostatic therapy...
  21. ncbi Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis
    Ioannis Mylonas
    First Department of Obstetrics and Gynecology, Ludwig Maximilians University Munich, 80337 Munich, Germany
    Oncol Rep 13:81-8. 2005
    ..Therefore, inhibin/activin subunits might be useful prognostic markers for breast cancer...
  22. ncbi Invasive hydatidiform mole: immunohistochemical labelling of inhibin/activin subunits, Ki67, p53 and glycodelin A in a rare case
    Josef Makovitzky
    Department of Obstetrics and Gynaecology, University of Rostock, Rostock, Germany
    Acta Histochem 111:360-5. 2009
    ..Therefore, since the pathological diagnosis of an invasive mole is difficult, the immunohistochemical detection of inhibin/activin subunits, Ki67, p53 and glycodelin A might be additional useful tumour markers...
  23. ncbi Tumor location, interval between surgery and radiotherapy, and boost technique influence local control after breast-conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results
    Hellen Knauerhase
    Department of Radiation Therapy, University of Rostock, Rostock, Germany
    Int J Radiat Oncol Biol Phys 72:1048-55. 2008
    ..To obtain long-term data on local tumor control after treatment of invasive breast cancer by breast-conserving surgery and adjuvant radiotherapy (RT), in consideration of the interstitial high-dose-rate boost technique...
  24. ncbi Concurrent radiotherapy and taxane chemotherapy in patients with locoregional recurrence of breast cancer. A retrospective analysis
    Sabine Semrau
    Department of Radiotherapy, University of Rostock, Rostock, Germany
    Strahlenther Onkol 182:596-603. 2006
    ..CONCLUSION: Concurrent irradiation and taxane chemotherapy weekly, in particular with paclitaxel, is recommended due to response and acceptable side effects for treatment of inoperable locoregional breast cancer recurrence...
  25. ncbi Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus
    Berith Kortmann
    Department of Radiotherapy, University of Rostock, Germany
    Strahlenther Onkol 182:318-24. 2006
    ..CONCLUSION: Concurrent RCT shows good local effectiveness with a good long-term survival. Further evaluation in phase II studies is recommended...
  26. ncbi Pathologic nipple discharge: surgery is imperative in postmenopausal women
    Steffi Lau
    Department of Obstetrics and Gynecology, University of Rostock, Universitatsfrauenklinik, Suedring 81, 18059 Rostock, Germany
    Ann Surg Oncol 12:546-51. 2005
    ....
  27. ncbi Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly
    Toralf Reimer
    Department of Obstetrics and Gynecology, University of Rostock, Klinikum Suedstadt, Rostock, Germany
    Drugs Aging 27:791-800. 2010
    ..Future studies that include QOL measurements should also provide details on the data collection and quality control methodologies used...
  28. ncbi Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study
    Bernd Gerber
    University of Rostock, Rostock, Germany
    J Clin Oncol 29:2334-41. 2011
    ..We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer...
  29. ncbi Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?
    Bernd Gerber
    Department of Obstetrics and Gynecology, University of Rostock, Suedring 81, Rostock, Germany
    Breast Cancer Res Treat 128:613-24. 2011
    ..Nonetheless, a rational and evidence-based approach to the management of clinically and sonographically N0 patients with planned breast-conserving surgery and limited tumor size is needed now...
  30. ncbi Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue
    Claudia Röwer
    Proteome Center Rostock, University of Rostock, 18055, Rostock, Germany
    Anal Bioanal Chem 395:2443-56. 2009
    ....
  31. ncbi The effects of different lignans and isoflavones, tested as aglycones and glycosides, on hormone receptor-positive and -negative breast carcinoma cells in vitro
    Conrad Theil
    Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Rostock, Südring 81, 18059 Rostock, Germany
    Arch Gynecol Obstet 284:459-65. 2011
    ..In this study, the effects of the lignan secoisolariciresinol and the isoflavone glycosides and aglycones genistein, genistin, daidzein and daidzin were tested on MCF-7 and BT20 cells in vitro...
  32. ncbi Unexpected metastatic lobular carcinoma of the breast with intraabdominal spread and subsequent port-site metastasis after diagnostic laparoscopy for exclusion of ovarian cancer
    Ioannis Mylonas
    First Department of Obstetrics and Gynecology, Ludwig Maximilians University Munich, Munich 80337, Germany
    Gynecol Oncol 95:405-8. 2004
    ..Although lobular carcinomas metastasize primarily to lymph nodes, bone, lung and liver, they can also spread to the gastrointestinal tract, peritoneum and gynecologic organs...
  33. ncbi Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer
    Toralf Reimer
    Department of Obstetrics and Gynaecology, University of Rostock, Faculty of Medicine, Germany
    Breast Cancer Res 4:R9. 2002
    ..The objective of the present study was to examine the prognostic and predictive significance of the apoptosis-related marker Fas ligand (FasL):Fas ratio in breast cancer...
  34. ncbi Management of early invasive breast cancer in very young women (<35 years)
    Steffi Hartmann
    Department of Obstetrics and Gynecology, University of Rostock, Südring 81, Rostock, Germany
    Clin Breast Cancer 11:196-203. 2011
    ..To give an overview about current treatment recommendations and special problems concerning the management of women <35 years with early breast cancer...
  35. ncbi Controversies in preservation of ovary function and fertility in patients with breast cancer
    Bernd Gerber
    Department of Gynecology and Obstetrics, University of Rostock, Klinikum Südstadt Rostock, Südring 81, Rostock, Germany
    Breast Cancer Res Treat 108:1-7. 2008
    ..Therefore it seems necessary to inform breast cancer patients about the possible negative effects of preservation of ovarian function...
  36. ncbi The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
    Wolfgang Janni
    I Frauenklinik, Klinikum der Ludwig Maximilians Universtitaet, Muenchen, Germany
    Cancer 103:884-91. 2005
    ..If the persistence of ITCs after adjuvant therapy confers a similar risk for recurrence, then it would be an indication to consider secondary adjuvant therapy...
  37. ncbi Desmopressin-induced Moschcowitz-like syndrome after treatment of uterine atonic bleeding in a 28-year-old pregnant woman: case report and overview of the literature
    Max Dieterich
    Department of Obstetrics and Gynecology, Südstadt Hospital, University of Rostock, Germany
    Blood Coagul Fibrinolysis 22:749-51. 2011
    ..In conclusion, desmopressin should not be administered in pregnant patients owing to its potential risk of triggering the development of thrombotic-thrombocytopenic purpura...
  38. ncbi Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps
    Ioannis Mylonas
    First Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University Munich, Maistrasse 11, 80337 Munich, Germany
    Arch Gynecol Obstet 272:59-66. 2005
    ..Therefore, endometrial polyps may be tumours of dysregulation with mainly proliferating characteristics, being unable to synchronise with normal endometrium...
  39. ncbi Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases
    Wolfgang Janni
    Department of Gynecology and Obstetrics, University Hospital, Ludwig Maximilians University, Maistrasse 11, 80337, Munich, Germany
    J Cancer Res Clin Oncol 129:503-10. 2003
    ....
  40. ncbi Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis
    Christian Jackisch
    Department of Obstetrics and Gynecology, University of Marburg, Pilgrimstein 3, D-35037 Marburg, Germany
    Clin Breast Cancer 3:276-80. 2002
    ..The application of both schedules is safe and feasible in an outpatient setting. Although, results obtained from this interim analysis are encouraging, caution is recommended until the results obtained show statistical difference in pCR...
  41. ncbi Prognostic value of Ca 125 levels during primary therapy
    Susanne Markmann
    Department of Obstetrics and Gynaecology in Klinikum Südstadt, University of Rostock, Südring 81, 18059 Rostock, Germany
    Anticancer Res 27:1837-9. 2007
    ..Complete cytoreductive surgery is the most important prognostic factor. We investigated the suitability of Ca 125 as a prognostic factor in patients with ovarian cancer at various...
  42. ncbi Postoperative infections due to bladder catheters after anterior colporrhaphy: a prospective, randomized three-arm study
    Ute Kringel
    Department of Obstetrics and Gynaecology, University of Rostock, Rostock, Germany
    Int Urogynecol J 21:1499-504. 2010
    ..If IUCs have no higher rate of infections or complications compared to SUC for 96 h, the former could be considered sufficient...
  43. ncbi Expression pattern of progranulin in the human placenta and its effect on cell proliferation in the choriocarcinoma cell line BeWo
    Johannes Stubert
    Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany
    J Reprod Dev 57:229-35. 2011
    ..The observed effect of progranulin on cell proliferation in BeWo cells may indicate a growth stimulating effect also on the small part of proliferating extravillous trophoblast cells during placental development...
  44. ncbi Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:542-51. 2008
    ..We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen...
  45. ncbi Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:552-62. 2008
    ..The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial...
  46. ncbi CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)
    Gunter von Minckwitz
    German Breast Group, Schleussnerstrase 42, 63263 Neu Isenburg, Germany
    Eur J Cancer 42:1780-8. 2006
    ..79 (95% CI=0.54-1.14; P=0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer...
  47. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  48. ncbi Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg Frankfurt, Germany
    J Clin Oncol 23:2676-85. 2005
    ..Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer...